Cutler Group’s Adamas Pharmaceuticals ADMS Stock Holding History

Cutler Group’s Portfolio ADMS Stock Details ADMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-5,600	Closed	-$1K	–	6690
2021 Q1	$1K	Buy	+5,600	New	+$29.2K	﹤0.01%	5503
2018 Q2	–	Sell	-7,400	Closed	-$9K	–	5165
2018 Q1	$9K	Sell	7,400 -16,300	-69%	-$514K	﹤0.01%	2908
2017 Q4	$160K	Buy	23,700 +17,500	+282%	+$489K	0.01%	1102
2017 Q3	$8K	Buy	+6,200	New	+$114K	﹤0.01%	4042
2016 Q2	–	Sell	-26,700	Closed	-$37K	–	7540
2016 Q1	$37K	Buy	+26,700	New	+$450K	﹤0.01%	2647

Cutler Group's ADMS Position: Q4 2021 in Review

Cutler Group sold out of Adamas Pharmaceuticals (ADMS) in Q4 2021, closing a stake of 1,100 shares — an estimated $5K sold.

Cutler Group first reported a position in ADMS in Q2 2016 and held it in 18 quarters. The position peaked at $144K in Q2 2016. 0 funds tracked by Wall St. Rank hold ADMS as of Q4 2021.

Cutler Group reported no remaining Adamas Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
Cutler Group sold 1,100 Adamas Pharmaceuticals shares in Q4 2021, an estimated $5K.
Cutler Group first reported a position in Adamas Pharmaceuticals in Q2 2016 and held it in 18 quarters.
Cutler Group's Adamas Pharmaceuticals position peaked at $144K in Q2 2016.
0 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q4 2021.

Based on Cutler Group's 13F filing for Q4 2021, filed 18 Jan 2022.